Search research articles
Contact Us
Filters
Showing results (1-10 of 202) with videos related to
Page
of 21
Sort By:
Lancet (London, England)
|
October 12, 2004
Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer
John Crown
Lancet (London, England)
|
September 6, 2003
Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?
John Crown
Oncotarget
|
February 18, 2017
CDK8: a new breast cancer target
John Crown
Anticancer Research
|
June 28, 2007
EGFR and HER-2 antagonists in breast cancer
Norma O'Donovan, John Crown
Breast Cancer Research and Treatment
|
July 19, 2003
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy
John Crown, Mark Pegram
International Journal of Cancer
|
July 9, 2020
Drugging "undruggable" genes for cancer treatment: Are we making progress?
Michael J Duffy, John Crown
Clinical Chemistry
|
August 13, 2022
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers
Michael J Duffy, John Crown
Critical Reviews in Clinical Laboratory Sciences
|
January 18, 2014
Precision treatment for cancer: role of prognostic and predictive markers
Michael J Duffy, John Crown
Clinical Chemistry
|
July 19, 2019
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael J Duffy, John Crown
Journal of Personalized Medicine
|
January 21, 2022
Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
Michael J Duffy, John Crown
Page
of 21
Search research articles
Search
Showing results (1-10 of 202) with videos related to
Sort By:
Page
of 21
Lancet (London, England)
|
October 12, 2004
Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer
John Crown
Lancet (London, England)
|
September 6, 2003
Chemotherapy dose and schedule in adjuvant treatment of breast cancer: phoenix, turkey, or dodo?
John Crown
Oncotarget
|
February 18, 2017
CDK8: a new breast cancer target
John Crown
Anticancer Research
|
June 28, 2007
EGFR and HER-2 antagonists in breast cancer
Norma O'Donovan, John Crown
Breast Cancer Research and Treatment
|
July 19, 2003
Platinum-taxane combinations in metastatic breast cancer: an evolving role in the era of molecularly targeted therapy
John Crown, Mark Pegram
International Journal of Cancer
|
July 9, 2020
Drugging "undruggable" genes for cancer treatment: Are we making progress?
Michael J Duffy, John Crown
Clinical Chemistry
|
August 13, 2022
Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers
Michael J Duffy, John Crown
Critical Reviews in Clinical Laboratory Sciences
|
January 18, 2014
Precision treatment for cancer: role of prognostic and predictive markers
Michael J Duffy, John Crown
Clinical Chemistry
|
July 19, 2019
Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients
Michael J Duffy, John Crown
Journal of Personalized Medicine
|
January 21, 2022
Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer
Michael J Duffy, John Crown
Page
of 21